Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

NCT00012376 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Blastic Phase Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia
Chronic Phase Chronic Myelogenous Leukemia
Paroxysmal Nocturnal Hemoglobinuria
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia
Refractory Anemia With Ringed Sideroblasts
Relapsing Chronic Myelogenous Leukemia
Thrombocytopenia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: bryostatin 1
BIOLOGICAL: sargramostim
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)